Linda Summerton

Chief Executive Officer

Linda has over 25 years in the global pharmaceutical industry in large pharmaceutical companies, small biotechnology companies, private equity ventures and specialist service providers. Linda worked for 18 years at AstraZeneca, where she held a variety of roles, including project director for Iressa to first registrations in Oncology, Accolate to NDA in asthma, and culminating in being Head of Strategy and Portfolio for the Oncology and Infection Therapy Area Management Team (TAMT). She was also SVP Portfolio and Project Integration (PPI) at Merck KGaA, based in Darmstadt, leading the portfolio steering committees for Oncology, Cardiovascular and CNS development programmes as well as managing a department of commercial and development personnel.

Subsequently, Linda was Partner at Celtic Pharma Holdings Advisors LLP, where she took responsibility for identifying assets for investment, conducting due diligence on these assets and ensuring all investee companies had solid clinical development plans in place. She also managed assets once acquired, including roles as Head of Clinical and Preclinical Development at Cantab Biopharmaceuticals, Interim CEO at Novacta Biosystems Ltd. and CEO at Dialog Devices Ltd. Latterly Linda became a Senior Partner at TranScrip, a specialist service provider to the pharma and biotech industry, where she leads oncology services and directly supports clients working in oncology; Immodulon is her major commitment for the foreseeable future.

She has a first degree and PhD from Cambridge UK, and held a NATO post-doctoral Fellowship tenured at University of California, San Francisco.